Biological and Environmental Research Ontology

Last uploaded: December 23, 2022
Id http://purl.obolibrary.org/obo/NCIT_C26653
http://purl.obolibrary.org/obo/NCIT_C26653
Preferred Name

Lapatinib
Definitions
A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
Type http://www.w3.org/2002/07/owl#Class

All Properties

definition

A synthetic, orally-active quinazoline with potential antineoplastic properties. Lapatinib reversibly blocks phosphorylation of the epidermal growth factor receptor (EGFR), ErbB2, and the Erk-1 and-2 and AKT kinases; it also inhibits cyclin D protein levels in human tumor cell lines and xenografts. EGFR and ErbB2 have been implicated in the growth of various tumor types.
prefLabel
Lapatinib
label
Lapatinib
Has_Salt_Form
CHEBI_ID
CHEBI:49603
code
C26653
Has_Target
prefixIRI
NCIT:C26653
in_subset
Preferred_Name
Lapatinib
FDA_UNII_Code
0VUA21238F
Contributing_Source
FDA
Chemical_Formula
C29H26ClFN4O4S
Maps_To
Lapatinib
CAS_Registry
231277-92-2
NSC Number
727989
Legacy Concept Name
GW572016
PubMedID_Primary_Reference
12214266
type
ALT_DEFINITION
A drug used with another anticancer drug to treat breast cancer that is HER2 positive and has advanced or metastasized (spread to other parts of the body) after treatment with other drugs. Lapatinib is also being studied in the treatment of other types of cancer. It is a type of ErbB-2 and EGFR dual tyrosine kinase inhibitor.
Is_Value_For_GDC_Property
subClassOf
Semantic_Type
Organic Chemical
Pharmacologic Substance
UMLS_CUI
C1506770
Add comment
Add proposal
Delete Subject Author Type Created
No notes to display